These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38224653)

  • 1. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
    Cheng Y; Wu L; Huang D; Wang Q; Fan Y; Zhang X; Fan H; Yao W; Liu B; Yu G; Pan Y; Xu F; He Z; Dong X; Ma R; Min X; Ge X; Chen H; Liu Q; Hu Y; Liu Y; Yang C; Yang Y; Li X; Zhou L
    Lung Cancer; 2024 Feb; 188():107455. PubMed ID: 38224653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
    Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
    Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
    Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
    Weiss JM; Csoszi T; Maglakelidze M; Hoyer RJ; Beck JT; Domine Gomez M; Lowczak A; Aljumaily R; Rocha Lima CM; Boccia RV; Hanna W; Nikolinakos P; Chiu VK; Owonikoko TK; Schuster SR; Hussein MA; Richards DA; Sawrycki P; Bulat I; Hamm JT; Hart LL; Adler S; Antal JM; Lai AY; Sorrentino JA; Yang Z; Malik RK; Morris SR; Roberts PJ; Dragnev KH;
    Ann Oncol; 2019 Oct; 30(10):1613-1621. PubMed ID: 31504118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
    Dómine Gómez M; Csőszi T; Jaal J; Kudaba I; Nikolov K; Radosavljevic D; Xiao J; Horton JK; Malik RK; Subramanian J
    Int J Cancer; 2021 Oct; 149(7):1463-1472. PubMed ID: 34109630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
    Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
    Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
    Hussein M; Maglakelidze M; Richards DA; Sabatini M; Gersten TA; Lerro K; Sinielnikov I; Spira A; Pritchett Y; Antal JM; Malik R; Beck JT
    Cancer Manag Res; 2021; 13():6207-6218. PubMed ID: 34408488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
    Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?
    Elijah J; Jain P; Holdsworth A; Baron J; Przespolewski E; Wang K; Attwood K; Billias C; Dy GK
    Support Care Cancer; 2024 Aug; 32(9):622. PubMed ID: 39215800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis.
    Dai HR; Yang Y; Wang CY; Chen YT; Cui YF; Li PJ; Chen J; Yang C; Jiao Z
    Acta Pharmacol Sin; 2024 Oct; 45(10):2212-2225. PubMed ID: 38760542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
    Daniel D; Kuchava V; Bondarenko I; Ivashchuk O; Reddy S; Jaal J; Kudaba I; Hart L; Matitashvili A; Pritchett Y; Morris SR; Sorrentino JA; Antal JM; Goldschmidt J
    Int J Cancer; 2021 May; 148(10):2557-2570. PubMed ID: 33348420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 13. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
    Abraham I; Onyekwere U; Deniz B; Moran D; Chioda M; MacDonald K; Huang H
    J Med Econ; 2021 Nov; 24(sup1):71-83. PubMed ID: 34873975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
    Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer.
    Li C; Rich B; Bullock JM; Barrière O; Marier JF; Beelen A
    Br J Clin Pharmacol; 2023 Mar; 89(3):1067-1079. PubMed ID: 36180417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
    Li C; Hart L; Owonikoko TK; Aljumaily R; Rocha Lima CM; Conkling PR; Webb RT; Jotte RM; Schuster S; Edenfield WJ; Smith DA; Sale M; Roberts PJ; Malik RK; Sorrentino JA
    Cancer Chemother Pharmacol; 2021 May; 87(5):689-700. PubMed ID: 33595690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
    Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
    J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
    Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
    Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.